PRESS RELEASE |
BioActor and INRA sign License Agreement on Olive Polyphenols and Bone Health
Licensed Technology Targets Prevention of Osteoporosis
BRUSSELS, BELGIUM/PARIS, France, November 14, 2005 – BioActor BVBA (BioActor) and INRA Transfert (fully-owned INRA subsidiary) announced today that they have signed a broad licence agreement concerning the patent and know-how owned by INRA covering the use of polyphenols from olive for the prevention of osteoporosis, acknowledged as a major public health problem. Under the terms of the agreement, BioActor has exclusive worldwide rights to use and exploit this technology for use in food, dietary supplements and phytomedicines.
The INRA team “Alimentation Squelette et Métabolismes” managed by Dr. Veronique Coxam at Clermont Ferrand (France) has extensively studied the effects of olives, olive oil and olive polyphenols on bone metabolism. They were the first scientists that discovered the bone sparing effect of Olive polyphenols. Several animal studies have confirmed these findings and BioActor and INRA are now collaborating to confirm these results in a human validation study.
According to Hans van der Saag, BioActor CEO, « with the licence on INRA’s patent covering the use of olive polyphenols for bone health we have accessed a truly innovative category of bioactive substances that can make an important contribution to the prevention of osteoporosis. Through our collaboration with Dr. Veronique Coxam we benefit from a decade of scientific knowledge on the interaction between nutrition and bone metabolism».
Pascale Charbonnel of INRA Transfert, commented that « We are very pleased to have licensed INRA’s technology to BioActor, a technology company dedicated to invest in the development and commercialization of this technology. We expect that INRA’s technology will prove to be of considerable value to BioActor’s product development program».
BioActor, based in Ghent, Belgium, is a product development company that supplies proprietary bioactive formulations to the nutrition & healthcare industry. The company focuses on the development of innovative bioactives that address the metabolic syndrome and ageing related chronic health conditions. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a health benefit to the consumer. INRA’s Research relates to the questions dependent on agriculture, food and food safety, environment and management of territories, with a very particular accent in favour of sustainable development.